Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19831
Title: Helicobacter pylori increases the risk of low-dose aspirin ulcers: A meta-analysis.
Authors: Sarri, Gino L;Grigg, Sam E;Yeomans, Neville D
Affiliation: Melbourne School of Medicine, University of Melbourne, Parkville, Victoria, Australia
Office for Research, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 8-Nov-2018
EDate: 2018-11-08
Citation: Journal of Gastroenterology and Hepatology 2018; online first: 8 November
Abstract: Owing to wide-spread use, low-dose aspirin (LDA) produces a substantial amount of peptic ulcer disease. Current guidelines are ambivalent about the need for Helicobacter pylori eradication to protect against LDA ulcers. This study aimed to determine, through meta-analysis, if (and by how much) infection alters the baseline risk of peptic ulcers during LDA therapy. Literature screening was performed in MEDLINE and EMBASE from inception to May 2018. Original studies reporting prevalence or incidence of uncomplicated ulcers in LDA users were included. Ulcer endpoints needed to be specified separately, according to Helicobacter pylori infection status. Meta-analysis was performed in MIX 2.0 Pro. Ten cross-sectional studies and seven randomized controlled trials were included (n = 5964). The pooled odds ratios (OR) with 95% confidence intervals (CI) for the risk of LDA ulcers in Helicobacter pylori-positive vs. -negative individuals were 1.68 (95%CI 1.40-2.02) and 1.65 (95%CI 1.29-2.08) under fixed- and random-effects models, respectively. Heterogeneity among studies was minimal (I2 = 26.9%). After adjusting for the protective effects of antisecretory drugs, the OR increased to 1.94 (95%CI 1.54-2.46). This analysis suggests Helicobacter pylori increases the risk of LDA ulcers by almost 70% in a population where some were taking proton pump inhibitors and/or other acid suppressants. Without antisecretory drugs, the risk almost doubles. Clinically, these findings may support the use of a test-and-treat approach to Helicobacter pylori in LDA users, particularly those at higher risk of developing for peptic ulcers.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19831
DOI: 10.1111/jgh.14539
ORCID: 0000-0001-7803-3169
0000-0001-9870-832X
0000-0002-6116-6595
PubMed URL: 30408229
Type: Journal Article
Subjects: Aspirin
Helicobacter pylori
Peptic Ulcer
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.